US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARS PHARMACEUTICALS INC

13.65

+0.16001.19%

Volume:181.14K

Turnover:2.49M

Market Cap:1.34B

PE:170.63

High:13.90

Open:13.45

Low:13.45

Close:13.49

Loading ...

Overview Company News Filings

BRIEF-ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website

ARS Pharmaceuticals Inc: Cash Price for Neffy Is $199 for Two Doses on GoodRx Website

THOMSON REUTERS

ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US

MT Newswires Live

BRIEF-ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S

ARS Pharmaceuticals Inc - Pharma Received $145 Million Upfront From Alk

THOMSON REUTERS

ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner and Global Allergy Leader Alk-AbellÓ a/S to Expand Reach of Neffy® (Epinephrine Nasal Spray) to Additional U.S. Pediatricians

THOMSON REUTERS

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ALK enters into neffy® co-promotion agreement in the USA

US High Growth Tech Stocks To Watch Now

Simply Wall St.

High Insider Ownership Growth Stocks To Know In April 2025

Simply Wall St.

Stock Track | ARS Pharmaceuticals Plummets 5% as Analysts Slash Revenue and Earnings Forecasts

Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year

Simply Wall St.

Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike

ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $32 From $28

THOMSON REUTERS

Stock Track | ARS Pharmaceuticals Plummets 5.59% Following Q4 Earnings and Analyst Price Target Cut

Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption

ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

Q4 2024 ARS Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":13.65,"timestamp":1746801780966,"preClose":13.49,"halted":0,"volume":181139,"delay":0,"floatShares":47453121,"shares":98119804,"eps":0.079999,"marketStatus":"Trading","change":0.16,"latestTime":"05-09 10:43:05 EDT","open":13.45,"high":13.9,"low":13.45,"amount":2492478.436448,"amplitude":0.033358,"askPrice":13.68,"askSize":295,"bidPrice":13.62,"bidSize":5,"shortable":3,"etf":0,"ttmEps":0.079999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746820800000},"marketStatusCode":2,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":13.49,"postHourTrading":{"tag":"盘后","latestPrice":13.49,"preClose":13.49,"latestTime":"17:30 EDT","volume":9794,"amount":132122.01,"timestamp":1746739846228},"volumeRatio":0.859902,"impliedVol":0.6454,"impliedVolPercentile":0.344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":47453121,"roa":"-0.66%","roe":"3.28%","lyrEps":0.082507,"volumeRatio":0.859902,"shares":98119804,"dividePrice":0,"high":13.9,"amplitude":0.033358,"preClose":13.49,"low":13.45,"week52Low":7.55,"pbRate":"5.22","psRate":"15.02","week52High":18.51,"institutionHeld":0,"latestPrice":13.65,"committee":-0.966667,"eps":0.079999,"divideRate":0,"volume":181139,"delay":0,"ttmEps":0.079999,"open":13.45,"prevYearClose":10.55,"prevWeekClose":14.46,"prevMonthClose":13.97,"prevQuarterClose":12.58,"fiveDayClose":14.46,"twentyDayClose":13.24,"sixtyDayClose":11.63,"earningDate":1747152000000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533098248","title":"BRIEF-ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2533098248","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533098248?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:15","pubTimestamp":1746620128,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx WebsiteMay 7 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS INC: CASH PRICE FOR NEFFY IS $199 FOR TWO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF0GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2533984975","title":"ARS Pharmaceuticals Inc: Cash Price for Neffy Is $199 for Two Doses on GoodRx Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533984975?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:04","pubTimestamp":1746619476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF0GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2532339842","title":"ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2532339842","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532339842?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:53","pubTimestamp":1746194001,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Friday it has signed an agreement with allergy immunotherapy firm ALK-Abello to co-promote Neffy nasal spray to up to 9,000 pediatricians in the US.Under the four-year deal, ARS will recognize all US revenue and will continue to have sole responsibility for all US commercialization activities, ARS said.ARS said it expects its operating expense outlook for 2025 to rise by about $3 million per quarter starting in Q3 under the deal but said its 2025 cash flow won't be impacted.The agreement follows a licensing deal between ARS and ALK-Abello, which provided ARS with $145 million upfront and gave ALK commercialization rights to Neffy in Canada, the UK, the EU and other countries outside the US, ARS said.Shares of ARS Pharmaceuticals were 3.5% higher in recent trading.Price: 14.55, Change: +0.39, Percent Change: +2.72","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4500","BK4139","BK4585","BK4008","SPRY","ALK","BK4588"],"gpt_icon":0},{"id":"2532841603","title":"BRIEF-ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S","url":"https://stock-news.laohu8.com/highlight/detail?id=2532841603","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532841603?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:31","pubTimestamp":1746192668,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S May 2 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS ANNOUNCES CO-PROMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA5TLV7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2532848156","title":"ARS Pharmaceuticals Inc - Pharma Received $145 Million Upfront From Alk","url":"https://stock-news.laohu8.com/highlight/detail?id=2532848156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532848156?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA5TLV7H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2532486478","title":"ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner and Global Allergy Leader Alk-AbellÓ a/S to Expand Reach of Neffy® (Epinephrine Nasal Spray) to Additional U.S. Pediatricians","url":"https://stock-news.laohu8.com/highlight/detail?id=2532486478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532486478?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA5TLV7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2532481668","title":"ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians","url":"https://stock-news.laohu8.com/highlight/detail?id=2532481668","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532481668?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States. New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season. “As a result of broad coverage from leading pharmaceutical benefit managers and health plans, millions of patients nationwide now have improved access to neffy,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. “This partnership extension with ALK allows us to efficiently reach healthcare professionals who represent about 55% of all community-use epinephrine prescriptions in the United States. By expanding direct promotion with ALK, the global leader in allergy immunotherapy  with substantial experience in the allergy space, we ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-announces-co-promotion-120000254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4500","LU0054578231.USD","BK4008","LU2065731478.USD","AKBLF","LU0053671581.USD","SPRY","BK4104","BK4585","BK4007","BK4588","AIT","ALK","LU1878469433.USD"],"gpt_icon":0},{"id":"2532184819","title":"ALK enters into neffy® co-promotion agreement in the USA","url":"https://stock-news.laohu8.com/highlight/detail?id=2532184819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532184819?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:59","pubTimestamp":1746187140,"startTime":"0","endTime":"0","summary":"Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way.Agreement does not change ALK’s revenue and earnings outlook for 2025.ALK  today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc.  to co-promote the neffy adrenaline  nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% of all adrenaline auto-injector prescriptions in the USA.Commenting on the new agreement, ALK's CEO Peter Halling said: “We are excited about expanding our partnership with ARS Pharma, which we firmly consider a win-win situation for all parties. More children, caregivers, and prescribers in the USA get access to an effective and needle-free anaphylaxis treatment. Although the agreement initially will have a limited financial impact for ALK, we are strengthening our capabilities in the USA. This may also support our respir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alk-enters-neffy-co-promotion-115900482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4008","ALK","BK4585","BK4007","BK4588","EBIT","SPRY","BK4500","AKBLF"],"gpt_icon":0},{"id":"2525401406","title":"US High Growth Tech Stocks To Watch Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2525401406","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525401406?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:08","pubTimestamp":1744024106,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped 9.4%, and over the past 12 months, it is down by 3.4%, yet earnings are expected to grow by 14% per annum in the coming years. In this environment, identifying high growth tech stocks involves looking for companies with strong fundamentals and innovative potential that can capitalize on anticipated earnings growth despite recent market volatility.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.Operations: ARS Pharmaceuticals generates revenue primarily from its pharmaceuticals segment, amounting to $89.15 million. The company is dedicated to advancing biopharmaceutical solutions for severe allergic reactions.ARS Pharmaceuticals has demonstrated robust growth, with a revenue surge from $0.03 million to $8","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-high-growth-tech-stocks-110826024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4567","LU0417517546.SGD","LU0320765992.SGD","LU2417539215.USD","SG9999001176.SGD","LU0058720904.USD","LU2462157665.USD","LU1093756325.SGD","LU2362541273.HKD","LU2362540622.SGD","LU1559883803.SGD","SPRY","LU0289739699.SGD","IE00BFTCPJ56.SGD","IE00B19Z9Z06.USD","VERX","LU2362541513.USD","IE00B19Z3B42.SGD","BK4585","IE0002141913.USD","SG9999013999.USD","LU0566484027.USD","LU2236285917.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU0234570918.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","VRTX","SG9999001176.USD","BK4532","CLSK","LU2237438978.USD","CLSKW","LU1093756168.USD","LU0889565916.HKD","LU1069344957.HKD","BK4023","LU1430594728.SGD","LU1815336091.USD","LU0109394709.USD","LU0061475181.USD","LU1035775433.USD","LU1585245621.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","LU0256863811.USD","IE0002270589.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0757428866.USD","IE0009355771.USD","BK4588"],"gpt_icon":0},{"id":"2524669258","title":"High Insider Ownership Growth Stocks To Know In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524669258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524669258?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:06","pubTimestamp":1743678379,"startTime":"0","endTime":"0","summary":"As the U.S. market navigates through a period of volatility fueled by recent tariff announcements, investors are keeping a keen eye on companies that can withstand economic headwinds. In this environment, growth stocks with high insider ownership often stand out as they suggest strong confidence from those closest to the company, potentially offering resilience and alignment with shareholder interests.Top 10 Growth Companies With High Insider Ownership In The United States. Underneath we present a selection of stocks filtered out by our screen.Overview: Joint Stock Company Kaspi.kz, with a market cap of $17.92 billion, offers payments, marketplace, and fintech solutions for consumers and merchants in Kazakhstan, Azerbaijan, and Ukraine.Operations: The company's revenue segments consist of Fintech at 1.28 billion KZT, Payments at 587.10 million KZT, and Marketplace at 732.94 million KZT.Kaspi.kz's earnings are expected to grow at 15.8% annually, surpassing the US market","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-insider-ownership-growth-stocks-110619013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4613","BK4113","BK4585","LU1720051108.HKD","BK4196","LU2065171402.SGD","BK4539","LU2065171311.SGD","BK4588","TBBB","KSPI","BK4097","LU2065170008.USD","LU2357305700.SGD","SPRY","LU1720051017.SGD","MNDY","LU1548497426.USD","LU2065169927.USD","BK4139"],"gpt_icon":1},{"id":"1179611170","title":"Stock Track | ARS Pharmaceuticals Plummets 5% as Analysts Slash Revenue and Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1179611170","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179611170?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:30","pubTimestamp":1743006628,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc.  saw its stock plummet 5.02% during intraday trading on Wednesday, following a series of downgraded forecasts from analysts. The sharp decline comes as market experts paint a gloomy picture for the company's near-term financial performance.According to the latest analyst reports, ARS Pharmaceuticals is facing significant headwinds in its revenue and earnings projections. The consensus forecast for 2025 revenues has been drastically reduced from US$125 million to US$83 mi","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1103304234","title":"Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1103304234","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103304234?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:30","pubTimestamp":1743006625,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc.  saw its stock plummet 5.02% during Wednesday's intraday trading session, following a series of analyst downgrades that have raised concerns about the company's future performance. The sharp decline comes as a stark contrast to the stock's recent 14% gain over the past week.Analysts have significantly cut their revenue and earnings forecasts for ARS Pharmaceuticals in 2025. The consensus revenue estimate has been reduced from $125 million to $83 million, representing a 6","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2522874286","title":"ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2522874286","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522874286?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:16","pubTimestamp":1742984206,"startTime":"0","endTime":"0","summary":"The latest analyst coverage could presage a bad day for ARS Pharmaceuticals, Inc. , with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share  forecasts were both revised downwards, with analysts seeing grey clouds on the horizon. Surprisingly the share price has been buoyant, rising 14% to US$13.15 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-nasdaq-spry-101646429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","USAW.SI","NDAQ","TQQQ","MNQmain","SPRY","NQmain","BK4585","BK4112","USJW.SI","QID",".IXIC","LU2210149790.SGD","QLD","BK4588","TSYW.SI","PSQ","NVIW.SI","BK4139","LU2095319765.USD","LU2210150020.SGD","SQQQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"1168497902","title":"Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike","url":"https://stock-news.laohu8.com/highlight/detail?id=1168497902","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168497902?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:10","pubTimestamp":1742818218,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock soar 5.18% in pre-market trading on Monday, as investors reacted positively to a significant target price increase from a major financial institution.Raymond James, a well-respected investment bank and financial services company, raised its target price for ARS Pharmaceuticals from $28 to $32. This represents a substantial 14.3% increase in the firm's valuation of the pharmaceutical company's stock.The target price hike suggests that Raymond James analysts ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2521274121","title":"ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $32 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2521274121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521274121?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:29","pubTimestamp":1742815793,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q7159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1131332685","title":"Stock Track | ARS Pharmaceuticals Plummets 5.59% Following Q4 Earnings and Analyst Price Target Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=1131332685","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131332685?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:33","pubTimestamp":1742563985,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock plummet 5.59% in pre-market trading on Friday, following the company's fourth quarter and full year 2024 earnings release and a subsequent analyst price target cut.The decline comes as Leerink Partners lowered their price target on ARS Pharmaceuticals from $27 to $26, signaling some caution despite the company's progress with its flagship product, neffy, a needle-free epinephrine nasal spray. This adjustment in valuation likely contributed to investor conce","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1132725662","title":"Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=1132725662","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132725662?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:32","pubTimestamp":1742563968,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.During the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market ex","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2521400448","title":"ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400448","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400448?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:38","pubTimestamp":1742557093,"startTime":"0","endTime":"0","summary":"Profit margin: 9.0% . The move to profitability was driven by higher revenue.We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGM:SPRY Earnings and Revenue Growth March 21st 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates significantly. Earnings per share  also surpassed analyst estimates.Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are up 21% from a week ago.While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of ARS Pharmaceuticals' balance sheet and an in-depth analysis of the company's financial position.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-full-2024-earnings-113813678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2521215534","title":"ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2521215534","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521215534?lang=en_us&edition=fundamental","pubTime":"2025-03-21 15:03","pubTimestamp":1742540588,"startTime":"0","endTime":"0","summary":"Net Product Revenue: $7.3 million for the full year 2024, with $6.7 million in the fourth quarter.Total Revenue: $89.1 million for the full year 2024, including collaboration and supply agreement revenues.Collaboration Revenue: $73.5 million from ALK and $6 million from a Japanese licensing partner in Q4 2024.R&D Expenses: $19.6 million for the full year 2024.SG&A Expenses: $71.7 million for the full year 2024.Net Income: $49.9 million for Q4 2024, $8 million for the full year 2024.Cash Position: $314 million in cash, cash equivalents, and short-term investments at year-end 2024.Operating Expenses Forecast: $200 million to $210 million for the full year 2025, excluding certain costs.GuruFocus has detected 4 Warning Signs with SPRY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.ARS Pharmaceuticals Inc  successfully launched neffy 2 milligrams in the United States and secured FDA approval for the 1 milligram dose for children, represen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-q4-070308778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2521944225","title":"Q4 2024 ARS Pharmaceuticals Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2521944225","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521944225?lang=en_us&edition=fundamental","pubTime":"2025-03-21 12:40","pubTimestamp":1742532039,"startTime":"0","endTime":"0","summary":"Justin Chakma; Chief Business Officer; ARS Pharmaceuticals Inc. Richard Lowenthal; President, Chief Executive Officer, Co-Founder, Director; ARS Pharmaceuticals Inc. Thank you, Justin, and thank you to everyone dialing in today. The past six months have been extremely productive for ARS. Since September, we have successfully launched neffy 2 milligrams in the United States and secured FDA approval for the 1 milligram neffy dose for patients weighing 15 kilograms to less than 30 kilograms. The population of children at this lower weight range that will use neffy 1 milligram represents 23% of the current auto-injector market. ARS has also made significant strides in payer coverage, with over 51% commercially insured able to get neffy without a prior authorization as of April 1, and we anticipate over 80% with our prior authorization by early this summer with the addition of neffy to the Caremark formulary. Our commercial execution has established a strong foundation of health care provid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-ars-pharmaceuticals-inc-044039579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY","CVS","CI"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":117,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"date":"2025-05-14","symbol":"SPRY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.35,"defaultRemindTime":1747209600000,"name":null,"time":"Pre-Market","dateTimestamp":1747195200000,"actualEps":null},{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52},{"market":"US","date":"2025-01-13","symbol":"SPRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"SPRY","fiscalQuarterEnding":"2024/09","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-06","symbol":"SPRY","fiscalQuarterEnding":"2024/06","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2025-05-08","current":165.495893,"percent":0.969178,"low":-41.829007,"twenty":-28.534893,"median":-17.625827,"eighty":-10.844982,"high":184.020638,"avg":-9.297763,"sd":44.772355,"marketCap":1323636155},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.372359,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":863336730},{"date":"2024-06-07","current":-17.19688,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":854616157},{"date":"2024-06-14","current":-17.430851,"twenty":-27.557105,"median":-15.857321,"eighty":-9.95084,"marketCap":866243588},{"date":"2024-06-21","current":-15.071642,"twenty":-27.270827,"median":-15.857321,"eighty":-9.975764,"marketCap":749000328},{"date":"2024-06-28","current":-15.695565,"twenty":-26.781626,"median":-15.857321,"eighty":-9.988225,"marketCap":780006810},{"date":"2024-07-05","current":-17.723315,"twenty":-26.233342,"median":-15.924221,"eighty":-10.038073,"marketCap":880777877},{"date":"2024-07-12","current":-21.66183,"twenty":-26.100403,"median":-16.005127,"eighty":-10.100383,"marketCap":1076506294},{"date":"2024-07-15","current":-22.129772,"twenty":-26.078246,"median":-16.005127,"eighty":-10.103498,"marketCap":1099761155},{"date":"2024-08-02","current":-20.452979,"twenty":-26.05609,"median":-16.005127,"eighty":-10.106614,"marketCap":1016431235},{"date":"2024-08-09","current":-21.380681,"twenty":-25.915765,"median":-16.072487,"eighty":-10.122191,"marketCap":958752513},{"date":"2024-08-16","current":-29.271428,"twenty":-26.174258,"median":-16.163463,"eighty":-10.15023,"marketCap":1312589385},{"date":"2024-08-23","current":-27.693279,"twenty":-27.713295,"median":-16.214626,"eighty":-10.468009,"marketCap":1241822011},{"date":"2024-08-30","current":-28.060793,"twenty":-27.98643,"median":-16.295121,"eighty":-10.844982,"marketCap":1258302084},{"date":"2024-09-06","current":-25.401719,"twenty":-27.994212,"median":-16.393243,"eighty":-10.985179,"marketCap":1139063905},{"date":"2024-09-13","current":-27.304146,"twenty":-27.978649,"median":-16.401625,"eighty":-11.047488,"marketCap":1224372521},{"date":"2024-09-20","current":-32.125068,"twenty":-28.0393,"median":-16.454093,"eighty":-11.125375,"marketCap":1440552309},{"date":"2024-09-27","current":-31.368421,"twenty":-28.102738,"median":-16.474539,"eighty":-11.25311,"marketCap":1406622746},{"date":"2024-10-04","current":-30.265879,"twenty":-28.279129,"median":-16.592455,"eighty":-11.496117,"marketCap":1357182526},{"date":"2024-10-11","current":-30.071312,"twenty":-28.572704,"median":-16.658407,"eighty":-11.620736,"marketCap":1348457781},{"date":"2024-10-18","current":-34.870616,"twenty":-28.814446,"median":-16.809891,"eighty":-11.676815,"marketCap":1563668153},{"date":"2024-10-25","current":-33.292466,"twenty":-29.051193,"median":-16.869409,"eighty":-11.785716,"marketCap":1492900778},{"date":"2024-10-31","current":-30.849578,"twenty":-29.236068,"median":-16.900657,"eighty":-11.835564,"marketCap":1383356760},{"date":"2024-11-08","current":-34.892234,"twenty":-29.613,"median":-17.040899,"eighty":-11.890396,"marketCap":1564637569},{"date":"2024-11-15","current":-27.926178,"twenty":-29.784002,"median":-17.157809,"eighty":-12.003593,"marketCap":1371287052},{"date":"2024-11-22","current":-26.481379,"twenty":-29.677856,"median":-17.19688,"eighty":-12.129003,"marketCap":1300341655},{"date":"2024-11-29","current":-28.717849,"twenty":-29.625971,"median":-17.210989,"eighty":-12.243664,"marketCap":1410161242},{"date":"2024-12-06","current":-27.708469,"twenty":-29.56544,"median":-17.223194,"eighty":-12.275913,"marketCap":1360596650},{"date":"2024-12-13","current":-25.016789,"twenty":-29.525705,"median":-17.313866,"eighty":-12.298002,"marketCap":1228424404},{"date":"2024-12-20","current":-22.404276,"twenty":-29.458385,"median":-17.352861,"eighty":-12.329028,"marketCap":1100139577},{"date":"2024-12-27","current":-22.067816,"twenty":-29.271428,"median":-17.394358,"eighty":-12.329028,"marketCap":1083618046},{"date":"2025-01-03","current":-21.196979,"twenty":-29.200708,"median":-17.429503,"eighty":-12.355333,"marketCap":1040856437},{"date":"2025-01-10","current":-22.621986,"twenty":-29.176877,"median":-17.469847,"eighty":-12.383408,"marketCap":1110829979},{"date":"2025-01-17","current":-24.106368,"twenty":-29.123341,"median":-17.508842,"eighty":-12.41924,"marketCap":1183719085},{"date":"2025-01-24","current":-27.490759,"twenty":-29.064257,"median":-17.592246,"eighty":-12.455071,"marketCap":1349906247},{"date":"2025-01-31","current":-28.28243,"twenty":-29.064257,"median":-17.626125,"eighty":-12.501652,"marketCap":1388780437},{"date":"2025-02-07","current":-25.333457,"twenty":-29.025066,"median":-17.679674,"eighty":-12.537484,"marketCap":1243974080},{"date":"2025-02-14","current":-23.591782,"twenty":-29.002547,"median":-17.701176,"eighty":-12.573316,"marketCap":1158450862},{"date":"2025-02-21","current":-23.314697,"twenty":-28.938503,"median":-17.719962,"eighty":-12.598398,"marketCap":1144844895},{"date":"2025-02-28","current":-20.187599,"twenty":-28.816442,"median":-17.723315,"eighty":-12.627063,"marketCap":991291845},{"date":"2025-03-07","current":-21.355313,"twenty":-28.81066,"median":-17.742813,"eighty":-12.687977,"marketCap":1048631275},{"date":"2025-03-14","current":-23.651157,"twenty":-28.793317,"median":-17.742813,"eighty":-12.709476,"marketCap":1161366426},{"date":"2025-03-21","current":175.555688,"twenty":-28.745638,"median":-17.756493,"eighty":-12.709476,"marketCap":1404094395},{"date":"2025-03-28","current":154.945377,"twenty":-28.717849,"median":-17.742813,"eighty":-12.566149,"marketCap":1239253124},{"date":"2025-04-04","current":164.39177,"twenty":-28.699711,"median":-17.73561,"eighty":-12.404907,"marketCap":1314805373},{"date":"2025-04-11","current":162.428883,"twenty":-28.621548,"median":-17.723315,"eighty":-12.298002,"marketCap":1299106204},{"date":"2025-04-17","current":182.548472,"twenty":-28.599098,"median":-17.719962,"eighty":-12.05734,"marketCap":1460022683},{"date":"2025-04-25","current":179.604142,"twenty":-28.539723,"median":-17.692748,"eighty":-11.714201,"marketCap":1436473930},{"date":"2025-05-02","current":173.715482,"twenty":-28.5364,"median":-17.665522,"eighty":-11.168992,"marketCap":1389376424},{"date":"2025-05-08","current":165.495893,"twenty":-28.534893,"median":-17.625827,"eighty":-10.844982,"marketCap":1323636155}],"updateTime":1746800581241}}}